[technology opportunity 2000-028]

NH-7211 – A Broad Acting Anti-Alzheimer’s Compound

Printer friendly version

Description:

Our researchers have created novel small chemical compounds capable of disrupting the three key misfolded proteins responsible for Alzheimer’s disease (AD) and other CNS disorders.  Our lead compound, NH-7211 has been extensively tested in both in vitro and in vivo models and has shown a unique ability to inhibit Aß40/Aß42, tau and alpha-synuclein aggregation.  This data suggests that our researchers have created a class of compounds capable of modulating key regulatory domain(s) within these misfolding proteins.

In APP/PS1 transgenic AD mice, NH-7211 rescued long-term potentiation suggesting that it rescues memory deficits caused by Aß40 formation.  This key in vivo data is supported by cell culture studies showing that inhibition ofAß40 formation significantly reduces hippocampal cell death.  In addition, in vitro studies showed that NH-7211 effectively reduces Aß40 ggregation in a dose-dependent manner.  

An independent contract laboratory company has conducted in vitro experiments studying the pharmacokinetic characteristics of NH-7211.  Preliminary data suggests that NH-7211 possesses high blood brain barrier penetration and high bioavailability, which is consistent with its high metabolic stability.  An initial high dose (300 mg/kg) in vivo rat study measuring functional toxicity and mortality was negative.

Status of Development:

Ongoing research includes additional in vivo APP/PS1 mouse studies, in vivo pharmacokinetic studies and additional medicinal chemistry work is being conducted to develop second and third generation analogues of NH-7211.  Patent applications have been filed in various jurisdictions around the World. 

Status of Commercialization:

PARTEQ Innovations, the technology transfer office of Queen’s University, is seeking industrial partners willing to support ongoing development of the product and/or who are interested in licensing the intellectual property. 

Contact:

Perry Kim, PhD

Director, Commercial Development, Life Sciences

Phone: (613) 533-2342, FAX: (613) 533-6853

E-mail: pkim@parteqinnovations.com